UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study

Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864241228350-17562864241228350

2024

Volltextzugriff (PDF)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

Frontiers in neurology, 2022-10, Vol.13, p.919778-919778

2022

Volltextzugriff (PDF)

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis

Journal of the American Medical Directors Association, 2015-10, Vol.16 (10), p.898.e1-898.e7

2015

Volltextzugriff (PDF)

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients

Journal of hepatology, 2014-06, Vol.60 (6), p.1112-1117

2014

Volltextzugriff (PDF)

Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE

Current HIV research, 2013-10, Vol.11 (7), p.570

2013

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

AIDS Research and Treatment, 2012-01, Vol.2012, p.186987-10

2012

Volltextzugriff (PDF)

Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials

Current HIV research, 2012-04, Vol.10 (3), p.256

2012

Volltextzugriff (PDF)

Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis

International journal of geriatric psychiatry, 2020-11, Vol.35 (11), p.1402-1408

2020

Volltextzugriff (PDF)

Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease‐related neuropsychiatric symptoms: a Phase 3b study

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Volltextzugriff (PDF)

Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study

Journal of Alzheimer's disease, 2024-01, Vol.98 (1), p.265

2024

Volltextzugriff (PDF)

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson’s Disease Psychosis

CNS spectrums, 2023-04, Vol.28 (2), p.239-239

2023

Volltextzugriff (PDF)

The Postwar Hospitalization Experience of U.S. Veterans of the Persian Gulf War

The New England journal of medicine, 1996-11, Vol.335 (20), p.1505-1513

1996

Volltextzugriff (PDF)

P3‐002: PIMAVANSERIN IN ALZHEIMER'S DISEASE PSYCHOSIS: SUBGROUP ANALYSIS OF THE MORE SEVERE POPULATION

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_19), p.P1062-P1062

2018

Volltextzugriff (PDF)

PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: SUBGROUP ANALYSIS OF THE MORE SEVERE POPULATION

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P1062-P1062

2018

Volltextzugriff (PDF)

Health-Related Quality of Life in the Gender, Race, And Clinical Experience Trial

AIDS Research and Treatment, 2011-01, Vol.2011, p.349165-8

2011

Volltextzugriff (PDF)

Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis

Clinical neuropharmacology, 2018-11, Vol.41 (6), p.210-215

2018

Volltextzugriff (PDF)

A POST HOC ANALYSIS OF STUDY ACP-103-019 EVALUATING THE IMPACT OF A REDUCTION IN PSYCHOSIS ON THE SEVERITY OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER'S DISEASE

The American journal of geriatric psychiatry, 2019-03, Vol.27 (3), p.S175-S175

2019

Volltextzugriff (PDF)

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications

Movement disorders, 2018-11, Vol.33 (11), p.1769-1776

2018

Volltextzugriff (PDF)

Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients

Parkinsonism & related disorders, 2021-06, Vol.87, p.25-31

2021

Volltextzugriff (PDF)

122 Use of Pimavanserin in Patients With Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment

CNS spectrums, 2018-02, Vol.23 (1), p.77-77

2018

Volltextzugriff (PDF)

107 Examining Real World Treatment Pathways in Parkinson Disease Psychosis: Initial Findings from the INSYTE Observational Study

CNS spectrums, 2020-04, Vol.25 (2), p.269-270

2020

Volltextzugriff (PDF)

158 Open-label Study of Pimavanserin Patients with Comorbid Parkinson's Disease and Depression

CNS spectrums, 2020-04, Vol.25 (2), p.301-301

2020

Volltextzugriff (PDF)

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

Hepatology (Baltimore, Md.), 2013-12, Vol.58 (6), p.1897-1906

2013

Volltextzugriff (PDF)

Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson’s disease psychosis (PDP)

Parkinsonism & related disorders, 2016-01, Vol.22, p.e91-e92

2016

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Englisch
(48)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients

Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials

Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease‐related neuropsychiatric symptoms: a Phase 3b study

Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson’s Disease Psychosis

The Postwar Hospitalization Experience of U.S. Veterans of the Persian Gulf War

P3‐002: PIMAVANSERIN IN ALZHEIMER'S DISEASE PSYCHOSIS: SUBGROUP ANALYSIS OF THE MORE SEVERE POPULATION

PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: SUBGROUP ANALYSIS OF THE MORE SEVERE POPULATION

Health-Related Quality of Life in the Gender, Race, And Clinical Experience Trial

Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis

A POST HOC ANALYSIS OF STUDY ACP-103-019 EVALUATING THE IMPACT OF A REDUCTION IN PSYCHOSIS ON THE SEVERITY OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER'S DISEASE

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications

Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients

122 Use of Pimavanserin in Patients With Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment

107 Examining Real World Treatment Pathways in Parkinson Disease Psychosis: Initial Findings from the INSYTE Observational Study

158 Open-label Study of Pimavanserin Patients with Comorbid Parkinson's Disease and Depression

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson’s disease psychosis (PDP)

Suchergebnisse filtern